Skip to main content

Qiagen Value Stock - Dividend - Research Selection

Qiagen

ISIN: NL0012169213 , WKN: A2DKCH

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Qiagen N.V. (QGEN) Presents at German Investment Seminar 2026 - Slideshow

2026-01-13
2026-01-13. The following slide deck was published by Qiagen N.V.

Qiagen N.V. (QGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-13
Qiagen N.V. (QGEN) 44th Annual J.P.

Qiagen N.V. (QGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow

2026-01-13
2026-01-13. The following slide deck was published by Qiagen N.V.

CareDX Has Reached An Inflection Point, But Regulatory Risks Remain (Upgrade)

2025-12-22
CareDx, Inc. reports its first net profit in a decade with improved cash flow and margins. Click for this updated look at CDNA stock prospects.

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million

2025-12-18
VENLO, Netherlands, December 18, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of plans to return approximately $500 million to shareholders through a synthetic share repurchase that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split.

EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi

2025-12-18
INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.

Barclays Maintains Qiagen N.V. (QGEN) Overweight Recommendation

2025-12-16

Are Investors Undervaluing Qiagen N.V. (NYSE:QGEN) By 24%?

2025-12-12
Key Insights Qiagen's estimated fair value is US$59.85 based on 2 Stage Free Cash Flow to Equity Qiagen's US$45.44...

Citigroup Downgrades Qiagen N.V. (QGEN)

2025-12-12

Companies Are Just Now Tallying Up the Impact of the US Shutdown

2025-12-11
Firms with significant exposure to federal spending, government contracts and regulatory approvals are now tallying up the impact on revenue and profit, with warnings ranging from words of caution to guidance cuts. Clearfield Inc., a manufacturer of fiber-optic and connectivity products for telecommunications and broadband networks, said industrywide fiber supply constraints and delays in the federal Broadband Equity, Access, and Deployment program, a $42.5 billion initiative to expand broadband access known as BEAD, created uncertainty in the community broadband market. “The government shutdown did affect bookings and our forecast for a soft first quarter into next year,” Chief Executive Officer Cheri Beranek said during an earnings call.